Literature DB >> 3921597

Effect of different doses of naloxone on serum levels of prolactin and gonadotropins in young male volunteers.

U A Knuth, E Nieschlag.   

Abstract

The dose-response of serum prolactin (PRL) values to different doses of naloxone (NAL) in rats is bellshaped. To test the effect of different doses of NAL on serum FSH, LH and PRL in humans these hormones were measured in 4 male volunteers after subject blind infusion of 0.02, 0.2 and 0.5 mg/kg NAL in random order. A saline infusion served as control. On each occasion an adjusted volume of 100 ml was infused within 10 min via an antecubital vein. Consequently blood samples were taken every 15 min for 4 h. To compare the response to the different treatments for each hormone the average of an individual's hormone values (4 x 16) was set to 100%. Values at each timepoint were expressed in relation to the volunteer's mean. The means and SE of hormone values set to 100% were: LH = 5.7 +/- 0.7 ng/ml; FSH = 3.1 +/- 1.0 ng/ml and PRL = 186 +/- 37 muU/ml. NAL infusion did not affect FSH levels at any dose level. No overall effect of NAL on PRL levels was detectable. There was a significant difference in LH values between saline control and NAL infusions, although no significant difference could be detected between different doses of NAL. Higher doses of NAL merely sustained LH levels for a longer time period. Based on the data presented a short test is suggested for screening patients under different pathophysiological conditions for involvement of endogenous opioids in the regulation of LH secretion.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3921597     DOI: 10.1007/BF03350640

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  12 in total

1.  Effects of naloxone, morphine and methionine enkephalin on serum prolactin, luteinizing hormone, follicle stimulating hormone, thyroid stimulating hormone and growth hormone.

Authors:  J F Bruni; D Van Vugt; S Marshall; J Meites
Journal:  Life Sci       Date:  1977-08-01       Impact factor: 5.037

2.  Enkephalin analogues and naloxone modulate the release of growth hormone and prolactin--evidence for regulation by an endogenous opioid peptide in brain.

Authors:  C J Shaar; R C Frederickson; N B Dininger; L Jackson
Journal:  Life Sci       Date:  1977-09-15       Impact factor: 5.037

Review 3.  The neuroendocrinology of opioid peptides.

Authors:  A Grossman; L H Rees
Journal:  Br Med Bull       Date:  1983-01       Impact factor: 4.291

4.  The effect of naloxone on pulsatile gonadotrophin release in normal subjects.

Authors:  P J Moult; A Grossman; J M Evans; L H Rees; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1981-03       Impact factor: 3.478

5.  Constancy of opioid control of luteinizing hormone in different pathophysiological states.

Authors:  S L Lightman; H S Jacobs; A K Maguire; G McGarrick; S L Jeffcoate
Journal:  J Clin Endocrinol Metab       Date:  1981-06       Impact factor: 5.958

6.  Endocrine effects of naloxone-induced opiate receptor blockade.

Authors:  J E Morley; N G Baranetsky; T D Wingert; H E Carlson; J M Hershman; S Melmed; S R Levin; K R Jamison; R Weitzman; R J Chang; A A Varner
Journal:  J Clin Endocrinol Metab       Date:  1980-02       Impact factor: 5.958

7.  Disposition of naloxone: use of a new radioimmunoassay.

Authors:  B A Berkowitz; S H Ngai; J Hempstead; S Spector
Journal:  J Pharmacol Exp Ther       Date:  1975-12       Impact factor: 4.030

8.  Naloxone effects on serum growth hormone and prolactin in man.

Authors:  D Janowsky; L Judd; L Huey; N Roitman; D Parker
Journal:  Psychopharmacology (Berl)       Date:  1979-09       Impact factor: 4.530

9.  Endorphins and the regulations of the human menstrual cycle.

Authors:  J Blankstein; F I Reyes; J S Winter; C Faiman
Journal:  Clin Endocrinol (Oxf)       Date:  1981-03       Impact factor: 3.478

10.  The opioid control of LH and FSH release: effects of a met-enkephalin analogue and naloxone.

Authors:  A Grossman; P J Moult; R C Gaillard; G Delitala; W D Toff; L H Rees; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1981-01       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.